Patients at the Fred & Pamela Buffett Cancer Center now have access to a promising new therapy that has generated national attention for its potential to improve outcomes for people with advanced pancreatic cancer. Patients with previously treated metastatic pancreatic cancer can receive daraxonrasib through an Expanded Access Program (EAP), providing an opportunity to receive the investigational therapy while it awaits review by the U.S. Food and Drug Administration.